A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

NCT07040059 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Patient recruitment problems.

Conditions

HER 2 Positive Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: AUR103 Calcium
DRUG: Trastuzumab + CAPOX (Capecitabine + Oxaliplatin)

Sponsor

Aurigene Discovery Technologies Limited